Basilea Pharmaceutica AG (CH) - New research data on Basilea's novel oncology drug candidate presented
Basel, Switzerland, April 21, 2010 - New research data on Basilea's antitumor drug candidate BAL101553 (prodrug of BAL27862) was presented at the American Association of Cancer Research (AACR) Annual Meeting in Washington D.C. The novel, intravenous and orally bioavailable small molecule disrupts the intracellular microtubule network, a well established drug target in oncology. The data confirm that the compound elicits a unique microtubule phenotype and shows activity in a wide range of cancer types, including those resistant to current treatment options.
Despite progress in the development of agents with antitumor activity, cancer remains a significant challenge in healthcare. There is an increasing medical need for novel agents with new mechanisms of action that overcome drug resistance in cancer therapy.
BAL101553 (prodrug of BAL27862) - a unique mode of action
Microtubules are one of the components of the intracellular scaffold (cytoskeleton). They are involved in many essential cellular processes and are a well established target of anticancer drugs. In-vitro data generated in collaboration with Prof. Diane Braguer's team, Institut national de la santé et de la recherche médicale, Université de la Méditerranée, Marseille, France, confirm that BAL27862 suppresses microtubule dynamics in living cancer cells. Furthermore, the distinct microtubule phenotype induced by BAL27862 is associated with an apparent severing of the microtubules leading to their fragmentation (M.-A. Esteve et al., abstract #1977; selected for oral presentation).
Studies from the same group and from the group of Prof. Branimir Sikic, Stanford University, School of Medicine, California, USA (G. E. Duran et al., abstract #4412), further demonstrate that BAL27862 has broad activity against a panel of breast and ovarian cancer cell lines resistant to currently marketed microtubule-targeted therapeutics. BAL27862 not only overcomes P-glycoprotein-mediated resistance, but also resistance related to modifications in the expression of proteins involved in tumor cell survival and microtubule function, respectively. The distinct microtubule phenotype and anticancer profile associated with BAL27862 supports evaluation in cancer patients with treatment-refractory tumors.
Basilea also presented for the first time data characterizing BAL101553, a prodrug of BAL27862 (J. Pohlmann et al., abstract #4419). The high water solubility of BAL101553 allows intravenous administration in the absence of solubilizing excipients which are known to be associated with adverse side-effects in patients. This characteristic, together with a demonstration of favorable pharmacokinetic properties and efficacy in animal tumor models, confirms that BAL101553 has the potential to be conveniently administered as a prodrug of the active compound BAL27862.
The phase I clinical development program to investigate the drug candidate in humans is expected to be initiated in H2 2010.
Abstracts on BAL27862/BAL101553 at the AACR 101st Annual Meeting
* BAL27862: A unique microtubule-targeted drug that suppresses microtubule dynamics, severs microtubules, and overcomes Bcl-2- and tubulin subtype-related drug resistance - M.-A. Esteve, S. Honore, N. Mckay, F. Bachmann, H. Lane, D. Braguer; abstract #1977 (selected for oral presentation) * In vitro activity of the novel tubulin active agent BAL27862 in MDR1(+) and MDR1(-) human breast and ovarian cancer variants selected for resistance to taxanes - G. E. Duran, H. Lane, F. Bachmann, B. I. Sikic; abstract #4412 * BAL101553: A highly soluble prodrug of the potent microtubule destabilizer BAL27862 - J. Pohlmann, F. Bachmann, A. Schmitt-Hoffmann, G. Biringer, K. Burger, C. Bucher, C. Schlaefle, J. Spickermann, R. Defoin, M. Pruschy, H. Lane; abstract #4419
About Basilea Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland, and listed on the SIX Swiss Exchange (SIX:BSLN). Its integrated research and development operations are currently focused on antibiotics and antifungals, as well as on the development of dermatology and oncology drugs, all areas in which the medical challenge of rising resistance or non-response to current treatment options is commonly encountered. Basilea's products are targeted to satisfy high medical and patient needs in the hospital and specialty care setting.
The company owns a broad and diversified portfolio. Basilea is marketing Toctino® (alitretinoin), for the treatment of severe chronic hand eczema, in Denmark, France, Germany, Switzerland and the United Kingdom. The drug is approved in 11 additional European countries as well as in Canada and has been recommended for approval in 11 further European countries. Furthermore, a phase III clinical trial on alitretinoin for the treatment of severe chronic hand eczema is ongoing in the U.S. Basilea has entered into a license, co-development and co-promotion agreement with Astellas Pharma Inc. for its phase III compound isavuconazole for the treatment of life-threatening invasive fungal infections on a worldwide basis, including an option for Japan. Full rights to a third late-stage product, ceftobiprole for the treatment of potentially life-threatening resistant bacterial infections, will be transferred from Cilag GmbH International, a Johnson & Johnson company, back to Basilea.
Disclaimer This communication expressly or implicitly contains certain forward-looking statements concerning Basilea Pharmaceutica Ltd. and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
For further information, please contact: Media Relations
Adesh Kaul Head Public Relations & Corporate Communications +41 61 606 1460 firstname.lastname@example.org
Barbara Zink, Ph.D., MBA Head Corporate Development
+41 61 606 1233 email@example.com
The press release can also be downloaded from the following link:
Press release (PDF)<http://hugin.info/134390/R/1405990/359677.pdf>
Posted: April 2010